Recro Pharma Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Recro Pharma (REPH) Tops Q2 EPS by 29c, Revenues Beat; Raises FY19 Revenue Guidance
August 8, 2019 7:17 AM EDTRecro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.13), $0.29 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $31.26 million versus the consensus estimate of $23.59 million.
Our CDMO business has delivered record results, generating $56.3 million in year to date revenues, a 36% increase from the comparable six-month period in 2018, said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. We are very pleased with the sales... More
